# Puma Biotechnology

## Earnings Call
## Commercial Update




**November 5, 2026**


nerlynx®
(neratinib) tablets

# Forward-Looking Safe-Harbor Statement

*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*

Puma Biotechnology


# Puma's Pharmacy and Distributor Network




Copyright 2026 Puma Biotechnology

# $54.1 Million Net NERLYNX Revenue in Q3’26


*~5% increase in Q3’26 compared to Q3’25*




**Inventory Change ($)**

| Q3’25 | Q3’26 |
|---|---|
| $3.1 mil | -$1.5 mil |

*~1% increase in Q3’26 compared to Q2’26*





**Inventory Change ($)**

| Q2’26 | Q3’26 |
|---|---|
| -$1 mil | -$1.5 mil |


Copyright 2026 Puma Biotechnology

# 2,818 Ex-Factory Bottles Were Sold in Q3’26

*~4% decrease in Q3’26 compared to Q3’25*





*~4% decrease in Q3’26 compared to Q2’26*





Copyright 2026 Puma Biotechnology

# 2,899 bottles of U.S. Commercial Demand in Q3’26

*~5% increase in Q3’26 compared to Q3’25*




*~3% decrease in Q3’26 compared to Q2’26*




Copyright 2026 Puma Biotechnology

# Rest of World Partnerships – Timelines

| Region | Partner | Regulatory Approvals | Commercial Launches |
|---|---|---|---|
| Australia / SE Asia | Specialised Therapeutics | • 2019 – Ext. Adj. in Australia, Singapore<br>• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand<br>• 2022 – Ext. Adj. in the Philippines; mBC in Singapore<br>• 2023 – mBC in Malaysia<br>• 2024 – Ext. Adj. and mBC in Thailand | • 2020 – Singapore<br>• 2021 – Malaysia, Brunei, New Zealand<br>• Q1 2026 - Thailand |
| Israel | MEDISON | • 2020 – Approved in Ext. Adj. and mBC | • 2020 – Launched |
| Canada | Knight | • 2019 – Ext. Adj. approved<br>• 2021 – mBC approved | • 2020 – Launched |
| Latin America | PINT PHARMA | • 2019 – Ext Adj in Argentina<br>• 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina<br>• 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil<br>• 2022 – Ext. Adj. in Mexico; mBC in Ecuador<br>• 2023 – mBC in Colombia and Mexico<br>• 2024 – mBC in Brazil | • 2020 – Argentina<br>• 2021 – Chile and Peru<br>• 2022 – Brazil<br>• 2023 – Mexico and Colombia |
| Europe<br>Greater China<br>Middle East<br>North and West Africa<br>South Africa<br>Turkey | Pierre Fabre | • 2019 – Ext. Adj. EMA and Hong Kong<br>• 2020 – Ext. Adj. in China, Taiwan<br>• 2021 – mBC in Taiwan<br>• 2023 – Ext. Adj. in Morocco, South Africa, and UAE<br>• 2024 – Ext. Adj. in Syria, Saudi Arabia, Algeria, Turkey<br>• 2025 – Ext. Adj. in Lebanon | • 2019 – Germany, UK, Austria<br>• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, HK<br>• 2021 – China, Taiwan, Greece, Czech Republic, Luxembourg<br>• 2022 – Ireland, Spain<br>• 2023 – Slovakia<br>• 2024 – Morocco, South Africa, UAE, Turkey, Saudi Arabia<br>• 2025 – Libya, Algeria |
| South Korea | BIXINK THERAPEUTICS | • 2021 – Ext. Adj. in S. Korea | • 2022 – Launched |
| Russia/CIS | ER-KIM | • Distribution agreement executed | |

Copyright 2026 Puma Biotechnology

# Puma Biotechnology

## Earnings Call
## Commercial Update




**November 5, 2026**

nerlynx®
(neratinib) tablets

Puma Biotechnology